Compare AGNC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGNC | HALO |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 11.2B |
| IPO Year | 2008 | 2001 |
| Metric | AGNC | HALO |
|---|---|---|
| Price | $10.94 | $106.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | $11.03 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 15.8M | 2.2M |
| Earning Date | 04-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 13.13% | N/A |
| EPS Growth | ★ 58.06 | N/A |
| EPS | 0.37 | ★ 3.11 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $0.33 | $28.24 |
| Revenue Next Year | $1.16 | $12.56 |
| P/E Ratio | ★ $29.22 | $34.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $61.23 |
| 52 Week High | $12.19 | $109.66 |
| Indicator | AGNC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 71.86 |
| Support Level | $10.57 | $67.12 |
| Resistance Level | $11.19 | N/A |
| Average True Range (ATR) | 0.15 | 2.74 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 55.10 | 74.72 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.